Results 211 to 220 of about 1,006,484 (304)

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

Clinical Pharmacology &Therapeutics, EarlyView.
The potential of real‐world data (RWD), particularly from patient registries, has been increasingly recognized over the last decade by academia, regulators, and health technology assessment (HTA) bodies for its role in assessing a product's effectiveness and supporting regulatory submissions.
Sonia Zebachi, Julien Tanniou, Elisabeth Bakker, Sieta T. de Vries, Rossella Di Bidino, Entela Xoxi, Anna Glaser, Gianluigi Savarese, Jan Hillert, Peter G. M. Mol, Kelly Plueschke, Billy Amzal, Ghinwa Y. Hayek, Jeverson Moreira   +13 more
wiley   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

AI and the Future of Disputing: Naming, Blaming, Claiming, and Preventing

Conflict Resolution Quarterly, EarlyView.
ABSTRACT This paper explores the transformative impact of artificial intelligence (AI) on dispute resolution mechanisms. Our analysis builds on the longstanding framework for explaining the stages through which disputes evolve: the “naming, blaming, claiming” model by Felstiner, Abel, and Sarat (1981).
Ethan Katsh, Talia Schwartz‐Maor, Orna Rabinovich‐Einy   +2 more
wiley   +1 more source

Staggered Board and Sexually Diverse Policies Adoption: Benevolence Motivation or Deeper Entrenchment?

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Building sexually diverse workplaces has become increasingly crucial for corporates. To create sexually diverse workplaces, firms require a high level of commitment collectively from their stakeholders, especially from corporate leadership.
Nuttavuth Nundhapana, Sirimon Treepongkaruna, Pornsit Jiraporn   +2 more
wiley   +1 more source

Doing Good While Doing Well? ESG Management as an Obstacle to Impact‐Oriented Sustainable Finance in Large Spanish Banks

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Addressing environmental and social sustainability challenges demands significant private financing. In response, financial institutions globally—including major Spanish banks—have increasingly adopted sustainable finance (SF). However, persistent greenwashing concerns question whether these practices meaningfully advance sustainability ...
Clara García, Fabio Casalegno
wiley   +1 more source

Sustainability Standards and Decertification: A Bayesian Analysis of SA8000

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Social Accountability 8000 (SA8000) is widely recognized as the leading certification‐based standard for social sustainability. The common assumption is that the number of certified companies increases steadily over time. However, this prevailing narrative lacks empirical support owing to the absence of comprehensive studies on SA8000 ...
Teresa Turzo, Cecilia Chirieleison, Alessandro Montrone, Luca Scrucca   +3 more
wiley   +1 more source

Changes in the utilization of prenatal and delivery services in the United States prior to, during, and after the COVID-19 pandemic. [PDF]

Reprod Health
Silverstein H, Jennings Mayo-Wilson L, Austin A.   +2 more
europepmc   +1 more source

Economic burden of fungal diseases in the United States. [PDF]

Med Mycol
Benedict K, Gold JAW, Chiller T, Lyman M.   +3 more
europepmc   +1 more source